Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205594 | 0.83 | CHRM2 (0.41) | KCNH2 | |
| SCHEMBL5747972 | 0.78 | JAK2 (0.35) | KCNH2 | |
| SCHEMBL5747052 | 0.77 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL5656515 | 0.72 | KCNH2 (0.44) | KCNH2SLC2A1 | |
| SCHEMBL5748093 | 0.71 | ALDH1A1 (0.38) | KCNH2SLC2A1ALDH1A1 | |
| SCHEMBL3216303 | 0.71 | SIGMAR1 (0.41) | KCNH2SLC2A1 | |
| SCHEMBL3632495 | 0.70 | HRH2 (0.47) | HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL3910347 | 0.69 | HRH1 (0.48) | HRH2HRH1KCNH2HRH3 | |
| SCHEMBL1692682 | 0.69 | HRH2 (0.48) | HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL14922331 | 0.69 | HRH2 (0.54) | HRH2HRH1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |